Leonteq Securities AG Invests $1.59 Million in Axon Enterprise, Inc $AXON

Leonteq Securities AG acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,801 shares of the biotechnology company’s stock, valued at approximately $1,591,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AXON. Baillie Gifford & Co. lifted its holdings in shares of Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares during the period. Vanguard Group Inc. increased its position in shares of Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares in the last quarter. Jennison Associates LLC increased its position in shares of Axon Enterprise by 53.8% during the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock worth $677,412,000 after purchasing an additional 330,213 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Axon Enterprise by 23.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock worth $476,089,000 after purchasing an additional 156,647 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its position in shares of Axon Enterprise by 2,541.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 96,053 shares of the biotechnology company’s stock worth $68,931,000 after purchasing an additional 99,988 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Trading Down 2.2%

AXON opened at $389.84 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $31.42 billion, a PE ratio of 156.56, a PEG ratio of 7.24 and a beta of 1.44. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The firm has a 50-day moving average price of $419.15 and a two-hundred day moving average price of $503.93.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.47 EPS. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AXON shares. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a research report on Thursday, May 7th. Barclays dropped their target price on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $712.75.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 157 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director owned 1,159 shares in the company, valued at approximately $567,910. This trade represents a 11.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Erika Nardini sold 198 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total transaction of $100,302.84. Following the completion of the sale, the director owned 1,946 shares of the company’s stock, valued at $985,804.68. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 13,855 shares of company stock worth $7,109,828. Corporate insiders own 4.20% of the company’s stock.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Zacks Research upgraded Axon Enterprise from “hold” to “strong-buy,” signaling improved analyst confidence in the stock’s outlook. Zacks.com
• Positive Sentiment: Coverage highlighted strong momentum in Axon’s Connected Devices business, with demand for TASERs, body cameras, and counter-drone products supporting revenue growth and suggesting the core business remains healthy. Zacks article
• Positive Sentiment: Axon said its AI video tools helped HoneyBaked generate eight-figure operational gains, reinforcing the company’s push to expand its software and AI platform beyond hardware. Seeking Alpha article
• Neutral Sentiment: Several recent articles focused on Axon’s long-term valuation after a sharp pullback, noting that the stock remains down significantly year to date even though the company still has strong longer-term growth credentials. Yahoo Finance article
• Neutral Sentiment: Jim Cramer’s comments that the market may not favor high-multiple stocks like Axon right now are more of a macro/valuation caution than a company-specific negative. Yahoo Finance article
• Neutral Sentiment: Market commentary noted Axon has sometimes lagged peers despite daily gains, indicating the stock is still navigating choppy sentiment rather than reacting to a clear business setback. MarketWatch article

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.